India, April 26 -- Valneva SE (VALN) announced that France's national public health agency, the Haute Autorite de Sante (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte.
The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of th...